# | Filing Date | Period End Date | Type | Report Link |
---|---|---|---|---|
1 | 08-13-2025 | 06-30-2025 | 10-Q | |
2 | 05-15-2025 | 03-31-2025 | 10-Q | |
3 | 03-31-2025 | 12-31-2024 | 10-K |
# | Date | Analyst Firm | Upside/Downside | Price Target Change | Rating Change | Current Rating |
---|
– Rademikibart demonstrated rapid and significant improvement in lung function and asthma control in patients, with greatest im...
HC Wainwright & Co. analyst Brandon Folkes reiterates Connect Biopharma Hldgs (NASDAQ:CNTB) with a Buy and maintains $7 ...
Connect Biopharma Hldgs (NASDAQ:CNTB) reported quarterly losses of $(0.23) per share which missed the analyst consensus estimat...
Connect Biopharma Holdings Limited (NASDAQ:CNTB) ("Connect Biopharma" or the "Company"), a clinical-stage bioph...